2020
Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes
Shallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review Of Hematology 2020, 13: 447-460. PMID: 32182435, DOI: 10.1080/17474086.2020.1744433.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic stem cell transplantationStem cell transplantationAcute myeloid leukemiaMyelodysplastic syndromeMDS patientsRisk stratificationCell transplantationPrognostic toolLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeLow-risk MDS patientsSevere bone marrow failureLow-risk diseaseLow-risk patientsOnly curative optionPrognosis of patientsBone marrow failureAggressive therapyCurative optionPrognostic impactEtiologic roleDisease progressionMyeloid leukemiaAlloSCTPatients
1988
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Antin JH, Smith BR, Holmes W, David RN, Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Institute Mitteilungen 1988, 149-53. PMID: 3071331.Peer-Reviewed Original ResearchConceptsPhase I/II studyMicrograms/m2Bone marrow failureII studyMarrow failureGM-CSFSevere bone marrow failureErythrocyte transfusion requirementsMyalgia/arthralgiaLow-grade feverRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colony-stimulating factorSevere marrow failureLow back discomfortColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorRecombinant human GM-CSFGrade feverTransfusion requirementsIntravenous infusionMyelodysplastic syndromePlatelet countAplastic anemiaGranulocyte countMonocyte count
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply